Literature DB >> 14696465

Protective effect of IGF-1 on experimental liver cirrhosis-induced common bile duct ligation.

Nuh Zafer Cantürk1, Zeynep Cantürk, Meltem Ozden, Hakki Dalçik, Melda Yardimoglu, Feti Tülübas.   

Abstract

BACKGROUND/AIMS: The causes of malnutrition in liver cirrhosis are multifactorial. Levels of IGF-1 (insulin like growth factor-1) that is a crucial regulator of intermediary metabolism decreases. The aim of this study was to analyze the effect of IGF-1 supplementation during liver cirrhosis induced by common bile duct ligation.
METHODOLOGY: Rats were divided into five different groups: One sham and four experimental groups. Rats in three of four groups were treated with 2 micrograms/day IGF-1 with a different time of experiment in each group. Blood biochemical parameters, tissue malondialdehyde, glutathione levels and the activity of tissue antioxidant enzymes and conventional and immunohistochemical analysis of liver samples were studied for each group.
RESULTS: Serum albumin, total protein, fibrinogen levels decreased and prothrombin time was prolonged in the bile duct ligated and transected experimental group but not in the IGF-I treated rats compared with the rats in sham group. Liver malondialdehyde levels significantly increased in control group but not in IGF-1 treated groups. The activities of antioxidant enzymes were decreased compared with the other groups. Histopathology findings of liver biopsy demonstrated intense degree fibrosis and overexpression of fibroblast growth factor and desmin in the control group but a lesser degree of those in the IGF-1 treated groups.
CONCLUSIONS: IGF-1 treatment improves liver function and decreases oxidative liver damage and histopathological findings. Further studies are required to delineate the mechanisms of protective effects of IGF-1.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14696465

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  13 in total

1.  Morphological and serum hyaluronic acid, laminin and type IV collagen changes in dimethylnitrosamine-induced hepatic fibrosis of rats.

Authors:  Chun-Hui Li; Dong-Ming Piao; Wen-Xie Xu; Zheng-Ri Yin; Jing-Shun Jin; Zhe-Shi Shen
Journal:  World J Gastroenterol       Date:  2005-12-28       Impact factor: 5.742

Review 2.  Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies.

Authors:  Jing-Ting Li; Zhang-Xiu Liao; Jie Ping; Dan Xu; Hui Wang
Journal:  J Gastroenterol       Date:  2008-07-04       Impact factor: 7.527

Review 3.  Novel insights into the function and dynamics of extracellular matrix in liver fibrosis.

Authors:  Morten A Karsdal; Tina Manon-Jensen; Federica Genovese; Jacob H Kristensen; Mette J Nielsen; Jannie Marie B Sand; Niels-Ulrik B Hansen; Anne-Christine Bay-Jensen; Cecilie L Bager; Aleksander Krag; Andy Blanchard; Henrik Krarup; Diana J Leeming; Detlef Schuppan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-03-12       Impact factor: 4.052

Review 4.  Malnutrition in cirrhosis: contribution and consequences of sarcopenia on metabolic and clinical responses.

Authors:  Pranav Periyalwar; Srinivasan Dasarathy
Journal:  Clin Liver Dis       Date:  2012-01-23       Impact factor: 6.126

5.  Disruption of the growth hormone--signal transducer and activator of transcription 5--insulinlike growth factor 1 axis severely aggravates liver fibrosis in a mouse model of cholestasis.

Authors:  Leander Blaas; Jan-Wilhelm Kornfeld; Daniel Schramek; Monica Musteanu; Gernot Zollner; Judith Gumhold; Franziska van Zijl; Doris Schneller; Harald Esterbauer; Gerda Egger; Markus Mair; Lukas Kenner; Wolfgang Mikulits; Robert Eferl; Richard Moriggl; Josef Penninger; Michael Trauner; Emilio Casanova
Journal:  Hepatology       Date:  2010-04       Impact factor: 17.425

6.  Preventive effect of Qianggan-Rongxian Decoction on rat liver fibrosis.

Authors:  Chun-Hui Li; Li-Hui Pan; Zong-Wei Yang; Chun-Yu Li; Wen-Xie Xu
Journal:  World J Gastroenterol       Date:  2008-06-14       Impact factor: 5.742

7.  IGF-1R contributes to stress-induced hepatocellular damage in experimental cholestasis.

Authors:  Axelle Cadoret; Colette Rey; Dominique Wendum; Khaldoun Elriz; François Tronche; Martin Holzenberger; Chantal Housset
Journal:  Am J Pathol       Date:  2009-07-23       Impact factor: 4.307

8.  Amelioration of hepatic fibrosis via Padma Hepaten is associated with altered natural killer T lymphocytes.

Authors:  I Ginsburg; E Koren; A Horani; M Mahamid; S Doron; N Muhanna; J Amer; R Safadi
Journal:  Clin Exp Immunol       Date:  2009-07       Impact factor: 4.330

9.  Clinical significance of serum IGF-I, IGF-II and IGFBP-3 in liver cirrhosis.

Authors:  Yun-Lin Wu; Jing Ye; Shu Zhang; Jie Zhong; Rong-Ping Xi
Journal:  World J Gastroenterol       Date:  2004-09-15       Impact factor: 5.742

10.  IGF-1 decreases portal vein endotoxin via regulating intestinal tight junctions and plays a role in attenuating portal hypertension of cirrhotic rats.

Authors:  Tian-Yu Zhao; Li-Ping Su; Chun-Ye Ma; Xiao-Han Zhai; Zhi-Jun Duan; Ying Zhu; Gang Zhao; Chun-Yan Li; Li-Xia Wang; Dong Yang
Journal:  BMC Gastroenterol       Date:  2015-07-08       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.